Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
Authors:
- Dirk SchadendorfDSDirk Schadendorf
- Hussein TawbiHTHussein Tawbi
- Evan J. LipsonELEvan J. Lipson
- F. Stephen HodiFHF. Stephen Hodi
- Piotr RutkowskiPRPiotr Rutkowski
- Helen GogasHGHelen Gogas
- Christopher D. LaoCLChristopher D. Lao
- Jean-Jacques GrobJGJean-Jacques Grob
- Andriy MoshykAMAndriy Moshyk
- Jennifer Lord-BessenJLJennifer Lord-Bessen
- Melissa HamiltonMHMelissa Hamilton
- Shien GuoSGShien Guo
Open Access
- 22 March 2023
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 187, 164-173
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- Ono Pharmaceutical
This publication has 23 references indexed in Scilit:
- Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In VivoPLOS ONE, 2014
- The Prevention and Treatment of Missing Data in Clinical TrialsNew England Journal of Medicine, 2012
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to ApoptosisThe Journal of Immunology, 2011
- Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life QuestionnaireValue in Health, 2009
- Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy‐Melanoma questionnaireCancer, 2008
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth and Quality of Life Outcomes, 2007
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systemsJournal of Clinical Investigation, 2007
- Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In VivoThe Journal of Immunology, 2004
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001